GlobeNewswire by notified

Unibail-Rodamco-Westfield updates its Green Financing Framework

Share

Paris, Amsterdam, November 16, 2022

Press release

Unibail-Rodamco-Westfield updates its Green Financing Framework

Unibail-Rodamco-Westfield (“URW”) today announces the update of its Green Financing Framework (“Framework"), which establishes a clear framework for the financing and/or refinancing of eligible new development projects and the regeneration of standing assets.

URW first issued a Green Bond Framework in 2014. Since then, URW has established a strong track record in the sustainable finance market, issuing the first industry green bond on the Euro market1, the first international non-Swedish green bond on the SEK Corporate market2, and the largest sustainability-linked Revolving Credit Facility for a REIT in Europe3.

With the 2022 update to its Framework, URW imposes higher standards on energy performance and updates eligibility criteria to require assets and development projects to meet BREEAM4 certification level at least ‘Excellent’ rather than ‘Very Good’ and be closely connected to public transport.

The Framework clarifies the eligibility criteria, the allocation and the reporting process to make it easier for investors to understand and track commitments. URW has also formed a Green Financing Committee that will rule on the use of proceeds and support future green financing allocation.

The Framework is aligned with best market practices, including the most recent updates of the ICMA Green Bond Principles as well as the LMA Green Loan Principles, while taking into account the EU Taxonomy Technical Screening Criteria. ISS ESG has issued a second party opinion (SPO) on the new Framework confirming this alignment.

Commenting on the Framework, Fabrice Mouchel, Chief Financial Officer, URW, said: Sustainability is embedded within our business strategy and these updates to our Green Financing Framework demonstrate our commitment to continue beinga leaderin this area. Our efforts are supported by our wide-ranging Better Places 2030 sustainabilityprogram, which also addresses priorities likeclimate change, biodiversity loss and social inclusion.

More information on the Framework can be found on URW’s website: 
https://www.urw.com/en/investors/financing-activity/Sustainable-financing

For more information, please contact:
Investor Relations 
Audrey Arnoux
+33 6 61 27 07 39
audrey.arnoux@urw.com

Media Relations
UK/Global:
Cornelia Schnepf – Finelk
+44 7387 108 998
cornelia.schnepf@finelk.eu

France:
Nathalie Feld – Image7
+33 6 30 47 18 37
nfeld@image7.fr

United States:
Molly Morse – Kekst CNC
+1 212 521 4826
molly.morse@kekstcnc.com

About Unibail-Rodamco-Westfield

Unibail-Rodamco-Westfield is an owner, developer and operator of sustainable, high-quality real estate assets in the most dynamic cities in Europe and the United States.

The Group operates 80 shopping centres in 12 countries, including 45 which carry the iconic Westfield brand. These centres attract over 900 million visits annually and provide a unique platform for retailers and brands to connect with consumers. URW also has a portfolio of high-quality offices, 10 convention and exhibition centres in Paris, and a €3 Bn development pipeline of mainly mixed-use assets. Currently, its €55 Bn portfolio is 87% in retail, 6% in offices, 5% in convention and exhibition venues, and 2% in services (as at June 30, 2022).

URW is a committed partner to major cities on urban regeneration projects, through both mixed-use development and the retrofitting of buildings to industry-leading sustainability standards. These commitments are enhanced by the Group’s Better Places 2030 agenda, which strives to make a positive environmental, social and economic impact on the cities and communities where URW operates.

URW’s stapled shares are listed on Euronext Amsterdam and Euronext Paris (Ticker: URW), with a secondary listing in Australia through Chess Depositary Interests. The Group benefits from a BBB+ rating from Standard & Poor’s and from a Baa2 rating from Moody’s.

For more information, please visit www.urw.com


1 Issued in February 2014 through the Group’s first Green Bond Framework. List of outstanding green bonds available under: https://www.urw.com/en/investors/financing-activity/Sustainable-financing
2 Issued in June 2014 through the Group’s first Green Bond Framework.
3 As at January 1, 2022.
4 Or equivalent.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and

Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342

Novo Nordisk A/S - share repurchase programme6.5.2024 20:44:48 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024 and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme6.5.2024 20:40:01 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.3% of the share capital and 77.4% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000 A shares of DKK 0.10 and 183,871,750 B shares of DKK 0.10, corresponding to 28.2% of the capital and 77.3% of the votes in Novo Nordisk A/S. The transaction is in line with th

HiddenA line styled icon from Orion Icon Library.Eye